Et AAV-genterapiforsøg med AFTX-201 til voksne med BAG3-associeret dilateret kardiomyopati (DCM) (UPBEAT)
En fase 1/2 multicenter, åben-label, dosiseskalerings- og dosisudvidelsesundersøgelse til vurdering af sikkerhed, tolerabilitet, farmakodynamik og foreløbig effektivitet af AFTX-201 administreret til voksne deltagere med BCL2-associeret Athanogene 3 (BAG3) mutation-associeret dilateret kardiomyopati: UPBEAT-undersøgelsen
This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Participants will receive a single intravenous infusion of AFTX-201 and will be followed for safety and clinical assessments. The study includes short-term safety monitoring and long-term follow-up for up to 60 months
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Clinical Trials Information
- Telefonnummer: 2 (617) 430-7817
- E-mail: clinicaltrials@affiniatx.com
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, QC H1T 1C8
- Rekruttering
- Institut de Cardiologie de Montréal / Montreal Heart Institute
-
Kontakt:
- Jérémie Coordonnateur de recherche EPS / EP research coordinator, BScN
- Telefonnummer: 2293 514-376-3330
- E-mail: Jeremie.Cortial@icm-mhi.org
-
Ledende efterforsker:
- Rafik Tadros, MD
-
-
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami Hospital and Clinics
-
Kontakt:
- Lina Carceres
- Telefonnummer: 954 249 3587
- E-mail: caceresl@miami.edu
-
Ledende efterforsker:
- Joshua Hare, MD
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Rekruttering
- St. Lukes Hospital
-
Ledende efterforsker:
- Andrew Kao, MD
-
Kontakt:
- Amanda Huffman, RN, BSN
- Telefonnummer: 816-932-0391
- E-mail: amanda.huffman@bjc.org
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- NYU Langone
-
Ledende efterforsker:
- Tajinderpal Saraon, MD
-
Kontakt:
- Loriya Thao
- Telefonnummer: 646-877-6343
- E-mail: loriya.thao@nyulangone.org
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Methodist Hospital
-
Ledende efterforsker:
- Cindy Martin, MD
-
Kontakt:
- Jennifer (Garrett) Medley Sr. Clinical Trials Manager
- Telefonnummer: 346-238-4516
- E-mail: jmgarrett@houstonmethodist.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Male or female, 18 to 70 years of age
Truncating mutation in BAG3
Dilated cardiomyopathy with left ventricular ejection fraction (LVEF) < 50% by echocardiogram or cardiac MRI
NYHA Class II or III heart failure symptoms
Body weight ≤ 120 kg
Willing and able to sign informed consent and comply with study procedures
Exclusion Criteria:
Prior myocardial infarction when, in the investigator's judgment, the totality of clinical and imaging evidence supports that left ventricular dysfunction is due to coronary artery disease rather than BAG3-associated dilated cardiomyopathy
Prior heart transplant
Presence or requirement of a left ventricular assist device (LVAD)
IV therapy with positive inotropes, vasodilators, or diuretics for heart failure within 30 days prior to enrollment
Positive neutralizing antibodies to ATC-0187
Any condition that, in the investigator's opinion, would place the subject at undue risk or interfere with study participation or interpretation of results
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: AFTX-201
Participants will receive a single intravenous dose of AFTX-201 |
AFTX-201 is a gene therapy product consisting of the ATC-0187 capsid containing the BCL2-associated Athanogene 3 (BAG3) transgene. It is administered as a single intravenous infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Tidsramme: Baseline through 12 months
|
Safety and tolerability of AFTX-201 over 12 months. |
Baseline through 12 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in pharmacodynamic biomarkers
Tidsramme: Baseline through 12 months
|
Assessment of the extent of AFTX-201 transduction and myocardial BAG3 protein expression after a single IV dose |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including left ventricular ejection fraction (LVEF)
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including peak oxygen consumption (pVO2) by cardiopulmonary exercise test (CPET)
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in New York Heart Association (NYHA) functional class
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on features of heart failure (HF) including functional classification by New York Heart Association (NYHA) class |
Baseline through 12 months
|
|
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on quality of life |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels through 12 months
Tidsramme: Baseline through 12 months
|
Assessment of the change from baseline in NT-proBNP levels following a single intravenous dose of AFTX-201 |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels during long-term follow-up
Tidsramme: Baseline through 60 months
|
Assessment of the change from baseline in NT-proBNP levels during long-term follow-up following a single intravenous dose of AFTX-201 |
Baseline through 60 months
|
|
Number of participants with adverse events during long-term follow-up
Tidsramme: Baseline through 60 months
|
Safety and tolerability of AFTX-201 over 60 months |
Baseline through 60 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- AFTX-201-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .